Literature DB >> 31772332

Sequence of AR inhibitors affects outcome.

Peter Sidaway1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31772332     DOI： 10.1038/s41571-019-0307-0

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

Authors:  Daniel J Khalaf; Matti Annala; Sinja Taavitsainen; Daygen L Finch; Conrad Oja; Joanna Vergidis; Muhammad Zulfiqar; Katherine Sunderland; Arun A Azad; Christian K Kollmannsberger; Bernhard J Eigl; Krista Noonan; Deepa Wadhwa; Andrew Attwell; Bruce Keith; Susan L Ellard; Lyly Le; Martin E Gleave; Alexander W Wyatt; Kim N Chi
Journal:  Lancet Oncol       Date:  2019-11-11       Impact factor: 41.316
  1 in total
  2 in total

Review 1.  Advances in targeted therapy for acute myeloid leukemia.

Authors:  Jifeng Yu; Peter Y Z Jiang; Hao Sun; Xia Zhang; Zhongxing Jiang; Yingmei Li; Yongping Song
Journal:  Biomark Res       Date:  2020-05-20

Review 2.  Second generation androgen receptor antagonists and challenges in prostate cancer treatment.

Authors:  Yanhua Chen; Qianqian Zhou; William Hankey; Xiaosheng Fang; Fuwen Yuan
Journal:  Cell Death Dis       Date:  2022-07-21       Impact factor: 9.685
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.